Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16254014 | 1.00 | HSD17B10 (0.46) | HSD17B10TP53MAPTPOLBAHR | |
| Hydrochloric Acid SCHEMBL30929177 | 0.98 | HSD17B10 (0.45) | HSD17B10TP53MAPTPOLBAHR | |
| SCHEMBL4982973 | 0.80 | ALDH1A1 (0.52) | HSD17B10TP53MAPTPOLBCA12 | |
| SCHEMBL2905322 | 0.80 | AHR (0.49) | HSD17B10MAPTAHRPDK2LMNA | |
| SCHEMBL29124061 | 0.80 | CDK5 (0.47) | TP53MAPTPOLBAHRPDK2 | |
| SCHEMBL28986962 | 0.75 | NPC1 (0.59) | HSD17B10MAPTAHRPDK2CA9 | |
| SCHEMBL8944351 | 0.71 | CYP2C19 (0.47) | HSD17B10TP53MAPTPOLBCDK5 | |
| SCHEMBL6722121 | 0.71 | NPC1 (0.47) | HSD17B10MAPTLMNACA12CA1 | |
| SCHEMBL20143486 | 0.71 | P2RX4 (0.53) | P2RX4 | |
| SCHEMBL1235044 | 0.71 | AHR (0.70) | MAPTAHRPDK2CCNT1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129296-B1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | NIPPON CHEMIPHAR CO (JP) | 2025-10-22 | — | — | EP | claimed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | claimed |
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | UNIV CONNECTICUT (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | disclosed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| EP-4408432-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | disclosed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023052518-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2023-04-06 | — | — | WO | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-4001310-A2 | ION CHANNEL MODULATORS AND USES THEREOF | MedImmune Limited (GB) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | HSD17B10 3752/4885TP53 4065/4885MAPT 4724/4885 |
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | PLAT, SERPINE1, SERPINC1 | HSD17B10 931/4885TP53 4537/4885MAPT 2236/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | HSD17B10 3701/4885TP53 3342/4885MAPT 4732/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | HSD17B10 3752/4885TP53 4065/4885MAPT 4724/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | HSD17B10 3752/4885TP53 4065/4885MAPT 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.